NR565 ADVANCED PHARMACOLOGY MIDTERM EXAM
2026/2027 | Rated A Review | Chamberlain | Pass Guaranteed
- A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (20
Questions)
Q1: A 68-year-old male with liver cirrhosis is prescribed a drug that undergoes extensive
first-pass metabolism. The nurse practitioner recognizes that first-pass metabolism
primarily occurs in which organ, and what is the clinical implication for this patient?
A. Kidney; increased renal excretion requiring dose reduction
B. Liver; significantly reduced bioavailability necessitating dose adjustment or
alternative route
C. Small intestine; enhanced absorption requiring decreased dosing
D. Lung; increased drug distribution requiring loading dose
Correct Answer: B
Rationale: First-pass metabolism occurs primarily in the liver via hepatic enzymes
(especially CYP450), where a significant portion of an orally administered drug is
metabolized before reaching systemic circulation. In liver cirrhosis, impaired hepatic
function reduces first-pass extraction, paradoxically increasing bioavailability while
simultaneously decreasing overall drug metabolism, necessitating careful dose
adjustment or alternative administration routes to prevent toxicity. [CORRECT]
Q2: A patient on phenytoin for seizure control develops a fungal infection. The NP
avoids prescribing ketoconazole because ketoconazole inhibits which enzyme system,
and what is the mechanism of this interaction?
A. MAO enzyme; prevents neurotransmitter degradation
B. CYP3A4; competitively inhibits metabolism leading to phenytoin toxicity
,C. Acetylcholinesterase; increases acetylcholine at synapses
D. Xanthine oxidase; increases uric acid production
Correct Answer: B
Rationale: Ketoconazole is a potent CYP3A4 inhibitor that competitively blocks the
metabolism of CYP3A4 substrates like phenytoin. This inhibition reduces phenytoin
clearance, increases its plasma concentration, and elevates the risk of dose-dependent
toxicity including nystagmus, ataxia, and CNS depression. The NP should select an
antifungal with minimal CYP3A4 interaction or monitor phenytoin levels closely.
[CORRECT]
Q3: The NP is educating a patient about why a loading dose is administered for digoxin
but not for amoxicillin. Which pharmacokinetic principle best explains this difference?
A. Digoxin has a longer half-life; amoxicillin has a shorter half-life
B. Digoxin has a large volume of distribution; amoxicillin has a small volume of
distribution
C. Digoxin has a narrow therapeutic index; amoxicillin has a wide therapeutic index
D. Digoxin requires receptor saturation; amoxicillin does not require receptor binding
Correct Answer: B
Rationale: Digoxin has a large volume of distribution (Vd ~500-800 L in adults) due to
extensive tissue binding, meaning a large proportion of the drug distributes outside the
plasma compartment. A loading dose is necessary to rapidly achieve therapeutic
plasma concentrations despite this extensive tissue distribution. Amoxicillin has a
smaller Vd and distributes primarily in extracellular fluid, reaching steady-state quickly
without requiring a loading dose. [CORRECT]
Q4: A patient with renal impairment is prescribed a drug that is 80% excreted
unchanged by the kidneys. The NP calculates a dose reduction based on creatinine
clearance. Which pharmacokinetic parameter is most directly affected by renal
impairment in this scenario?
A. Absorption
,B. Distribution
C. Metabolism
D. Excretion
Correct Answer: D
Rationale: When a drug is predominantly excreted unchanged by the kidneys, renal
impairment directly reduces drug clearance, prolongs half-life, and increases the risk of
accumulation and toxicity. The NP must calculate dose adjustments based on
creatinine clearance (CrCl) using the Cockcroft-Gault equation to prevent adverse
effects while maintaining therapeutic efficacy. [CORRECT]
Q5: A 45-year-old female with depression is started on fluoxetine. The NP explains that
steady-state concentration will be reached in approximately 5 half-lives. If fluoxetine has
a half-life of 1-3 days (and its active metabolite norfluoxetine 4-16 days), approximately
how long will it take to reach steady state?
A. 3-5 days
B. 7-10 days
C. 2-4 weeks
D. 6-8 weeks
Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 5 half-lives. Given
fluoxetine's long half-life (1-3 days) and its active metabolite norfluoxetine's even longer
half-life (4-16 days), the effective half-life is prolonged. Therefore, 5 half-lives would
require approximately 2-4 weeks to reach steady-state plasma concentrations, which
has clinical implications for both therapeutic onset and washout periods after
discontinuation. [CORRECT]
Q6: The NP is comparing two antihypertensive agents. Drug A has an ED50 of 10 mg
and Drug B has an ED50 of 50 mg. Both drugs produce the same maximal response.
Which statement accurately describes this relationship?
A. Drug A is more potent but less efficacious than Drug B
, B. Drug A is more potent and equally efficacious to Drug B
C. Drug B is more potent and more efficacious than Drug A
D. Drug A and Drug B have identical potency and efficacy
Correct Answer: B
Rationale: Potency refers to the dose required to produce a given effect (lower ED50 =
higher potency), so Drug A is more potent than Drug B. Efficacy refers to the maximal
response a drug can produce, and since both drugs produce the same maximal
response, they have equal efficacy. This distinction is critical for selecting optimal
therapy based on both dose requirements and therapeutic ceiling. [CORRECT]
Q7: A patient taking warfarin is advised to avoid grapefruit juice. The NP explains that
grapefruit juice inhibits intestinal CYP3A4 and P-glycoprotein. What is the primary
clinical consequence of this inhibition?
A. Increased warfarin metabolism leading to subtherapeutic INR
B. Decreased warfarin absorption leading to reduced anticoagulation
C. Increased warfarin bioavailability and decreased efflux, increasing bleeding risk
D. Enhanced warfarin protein binding leading to decreased free drug concentration
Correct Answer: C
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal
CYP3A4 and P-glycoprotein (an efflux transporter). This dual inhibition increases the
bioavailability of CYP3A4 and P-glycoprotein substrates like warfarin by reducing
presystemic metabolism and decreasing drug efflux back into the intestinal lumen,
thereby increasing plasma concentrations and bleeding risk. [CORRECT]
Q8: The NP is prescribing a drug that is a weak base (pKa 8.5) for a patient with a
urinary tract infection. To promote ion trapping and enhanced renal excretion of this
drug, the NP should:
A. Acidify the urine with ammonium chloride to increase ionized fraction
B. Alkalinize the urine with sodium bicarbonate to increase ionized fraction
C. Maintain neutral urine pH to maximize tubular reabsorption
D. Acidify the urine to decrease ionized fraction and enhance reabsorption
2026/2027 | Rated A Review | Chamberlain | Pass Guaranteed
- A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (20
Questions)
Q1: A 68-year-old male with liver cirrhosis is prescribed a drug that undergoes extensive
first-pass metabolism. The nurse practitioner recognizes that first-pass metabolism
primarily occurs in which organ, and what is the clinical implication for this patient?
A. Kidney; increased renal excretion requiring dose reduction
B. Liver; significantly reduced bioavailability necessitating dose adjustment or
alternative route
C. Small intestine; enhanced absorption requiring decreased dosing
D. Lung; increased drug distribution requiring loading dose
Correct Answer: B
Rationale: First-pass metabolism occurs primarily in the liver via hepatic enzymes
(especially CYP450), where a significant portion of an orally administered drug is
metabolized before reaching systemic circulation. In liver cirrhosis, impaired hepatic
function reduces first-pass extraction, paradoxically increasing bioavailability while
simultaneously decreasing overall drug metabolism, necessitating careful dose
adjustment or alternative administration routes to prevent toxicity. [CORRECT]
Q2: A patient on phenytoin for seizure control develops a fungal infection. The NP
avoids prescribing ketoconazole because ketoconazole inhibits which enzyme system,
and what is the mechanism of this interaction?
A. MAO enzyme; prevents neurotransmitter degradation
B. CYP3A4; competitively inhibits metabolism leading to phenytoin toxicity
,C. Acetylcholinesterase; increases acetylcholine at synapses
D. Xanthine oxidase; increases uric acid production
Correct Answer: B
Rationale: Ketoconazole is a potent CYP3A4 inhibitor that competitively blocks the
metabolism of CYP3A4 substrates like phenytoin. This inhibition reduces phenytoin
clearance, increases its plasma concentration, and elevates the risk of dose-dependent
toxicity including nystagmus, ataxia, and CNS depression. The NP should select an
antifungal with minimal CYP3A4 interaction or monitor phenytoin levels closely.
[CORRECT]
Q3: The NP is educating a patient about why a loading dose is administered for digoxin
but not for amoxicillin. Which pharmacokinetic principle best explains this difference?
A. Digoxin has a longer half-life; amoxicillin has a shorter half-life
B. Digoxin has a large volume of distribution; amoxicillin has a small volume of
distribution
C. Digoxin has a narrow therapeutic index; amoxicillin has a wide therapeutic index
D. Digoxin requires receptor saturation; amoxicillin does not require receptor binding
Correct Answer: B
Rationale: Digoxin has a large volume of distribution (Vd ~500-800 L in adults) due to
extensive tissue binding, meaning a large proportion of the drug distributes outside the
plasma compartment. A loading dose is necessary to rapidly achieve therapeutic
plasma concentrations despite this extensive tissue distribution. Amoxicillin has a
smaller Vd and distributes primarily in extracellular fluid, reaching steady-state quickly
without requiring a loading dose. [CORRECT]
Q4: A patient with renal impairment is prescribed a drug that is 80% excreted
unchanged by the kidneys. The NP calculates a dose reduction based on creatinine
clearance. Which pharmacokinetic parameter is most directly affected by renal
impairment in this scenario?
A. Absorption
,B. Distribution
C. Metabolism
D. Excretion
Correct Answer: D
Rationale: When a drug is predominantly excreted unchanged by the kidneys, renal
impairment directly reduces drug clearance, prolongs half-life, and increases the risk of
accumulation and toxicity. The NP must calculate dose adjustments based on
creatinine clearance (CrCl) using the Cockcroft-Gault equation to prevent adverse
effects while maintaining therapeutic efficacy. [CORRECT]
Q5: A 45-year-old female with depression is started on fluoxetine. The NP explains that
steady-state concentration will be reached in approximately 5 half-lives. If fluoxetine has
a half-life of 1-3 days (and its active metabolite norfluoxetine 4-16 days), approximately
how long will it take to reach steady state?
A. 3-5 days
B. 7-10 days
C. 2-4 weeks
D. 6-8 weeks
Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 5 half-lives. Given
fluoxetine's long half-life (1-3 days) and its active metabolite norfluoxetine's even longer
half-life (4-16 days), the effective half-life is prolonged. Therefore, 5 half-lives would
require approximately 2-4 weeks to reach steady-state plasma concentrations, which
has clinical implications for both therapeutic onset and washout periods after
discontinuation. [CORRECT]
Q6: The NP is comparing two antihypertensive agents. Drug A has an ED50 of 10 mg
and Drug B has an ED50 of 50 mg. Both drugs produce the same maximal response.
Which statement accurately describes this relationship?
A. Drug A is more potent but less efficacious than Drug B
, B. Drug A is more potent and equally efficacious to Drug B
C. Drug B is more potent and more efficacious than Drug A
D. Drug A and Drug B have identical potency and efficacy
Correct Answer: B
Rationale: Potency refers to the dose required to produce a given effect (lower ED50 =
higher potency), so Drug A is more potent than Drug B. Efficacy refers to the maximal
response a drug can produce, and since both drugs produce the same maximal
response, they have equal efficacy. This distinction is critical for selecting optimal
therapy based on both dose requirements and therapeutic ceiling. [CORRECT]
Q7: A patient taking warfarin is advised to avoid grapefruit juice. The NP explains that
grapefruit juice inhibits intestinal CYP3A4 and P-glycoprotein. What is the primary
clinical consequence of this inhibition?
A. Increased warfarin metabolism leading to subtherapeutic INR
B. Decreased warfarin absorption leading to reduced anticoagulation
C. Increased warfarin bioavailability and decreased efflux, increasing bleeding risk
D. Enhanced warfarin protein binding leading to decreased free drug concentration
Correct Answer: C
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal
CYP3A4 and P-glycoprotein (an efflux transporter). This dual inhibition increases the
bioavailability of CYP3A4 and P-glycoprotein substrates like warfarin by reducing
presystemic metabolism and decreasing drug efflux back into the intestinal lumen,
thereby increasing plasma concentrations and bleeding risk. [CORRECT]
Q8: The NP is prescribing a drug that is a weak base (pKa 8.5) for a patient with a
urinary tract infection. To promote ion trapping and enhanced renal excretion of this
drug, the NP should:
A. Acidify the urine with ammonium chloride to increase ionized fraction
B. Alkalinize the urine with sodium bicarbonate to increase ionized fraction
C. Maintain neutral urine pH to maximize tubular reabsorption
D. Acidify the urine to decrease ionized fraction and enhance reabsorption
